Journal
CNS NEUROSCIENCE & THERAPEUTICS
Volume 27, Issue 11, Pages 1425-1428Publisher
WILEY
DOI: 10.1111/cns.13733
Keywords
burden analysis; major depressive disorder; rare variants; UK biobank; whole-exome sequencing
Categories
Funding
- 4th Three-year Action Plan for Public Health of Shanghai [15GWZK0101]
- Shanghai Pujiang Program [17PJD020]
- Shanghai Key Laboratory of Psychotic Disorders [13dz2260500]
- National Nature Science Foundation of China [30900799812735968167132681773818]
- Clinical Innovation Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory [2018GZR0201002]
- Natural Science Foundation of Guangdong Province [2020A0505100062]
- National Natural Science Foundation of China [32070582]
- National key research and development program [2016YFC09050002016YFC09050022016YFC09064002016YFC1200200]
Ask authors/readers for more resources
In this study, a wide-ranging investigation of rare disease-causing variants for major depressive disorder (MDD) was conducted using samples from the UK Biobank. The gene-based analysis highlighted FOXH1 as significantly associated with MDD, while the sphingolipid metabolism pathway was found to be less enriched with rare disease-causing variants in the MDD group, suggesting its involvement in the pathophysiology of MDD.
In the present study, we performed an exome-wide investigation of the burden of rare disease-causing variants for major depressive disorder (MDD) using 16,702 samples from UK biobank. Gene-based association analysis and candidate gene prioritization analysis indicated that FOXH1 have significant association with MDD. In addition, sphingolipid metabolism pathway was found to be less enriched with rare disease-causing variants in the MDD group, suggesting that this gene set may be involved in the pathophysiology of MDD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
